ROYALTY PHARMA OA DL-0001

Novartis’s Phase 3 HORIZON study of pelacarsen missed its primary endpoint for reducing cardiovascular events versus placebo. Royalty Pharma expects, based on its $500 million financing agreement with Ionis, to recover its invested capital and achieve a moderate positive return without making milestone payments to Ionis. The agreement covers investments in pelacarsen and Spinraza royalties; the claim on Spinraza revenues yields roughly a 1.1× return under current terms. The company reaffirmed its goal of generating at least $4.7 billion in portfolio revenue by 2030. » More on de.investing.com

Royalty Pharma’s stock rose to a new record high of $62.48 and is currently trading at $62.58, implying a market capitalization of $35.87 billion. Year to date the shares are up 69.78%. For Q2 2026 the company reported licensing revenue of $768 million (+14% year over year) and portfolio revenue of $773 million (+6%), after which BofA raised its price target from $62.00 to $63.00 and kept its rating at "Buy." However, an analysis by InvestingPro classifies the stock as overvalued relative to its fair value. » More on de.investing.com

Royalty Pharma’s stock rose to a record high of $60.44 and is trading near its 52-week high after gaining 69% last year. For Q2 2026 the company reported royalties of $768 million (+14%) and portfolio revenues of $773 million (+6%), after which the full-year guidance was raised for the second time. BofA raised its price target to $63.00 and reiterated a “buy” rating, citing strong sales of products such as Tremfya, Voranigo, Imdelltra and Evrysdi. » More on de.investing.com